Skip to main content
SpringerLink
Log in

Novel Thrombolytic Drugs

  • Chapter
Acute Coronary Care 1986

Part of the book series: Acute Coronary Care Updates ((ACCU,volume 1))

  • 28 Accesses

Abstract

The demonstration by Rentrop in 1979 (1) of the feasibility of intracoronary thrombolysis and by DeWood in 1980 (2) of a high incidence of complete coronary occlusion early in the course of acute transmural myocardial infarction produced a surge of interest in thrombolytic drugs. Streptokinase and Urokinase have been widely available for years and will not be discussed here. Major efforts have been focused in the past five years in developing thrombolytic drugs which have a greater specificity for the fibrin thrombus than for normal coagulation proteins. Such drugs might produce thrombolysis without systemic fibrinogen breakdown, or clot-specific lysis, reducing susceptibility to iatrogenic hemorrhagic complications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rentrop, K.P., Blanke, H., Karsch, K.R., Kreuzer, H. Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction: comparison with conventionally treated patients. Clin. Cardiol. 2: 92 (1979).

    PubMed  CAS  Google Scholar 

  2. DeWood, M.A., Spores, J., Notske, M.D., et. al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N. Engl. J. Med. 303: 897 (1980).

    Article  PubMed  CAS  Google Scholar 

  3. Collen, D. On the regulation and control of fibrinolysis Thromb. Haemost. 43: 77 (1980).

    CAS  Google Scholar 

  4. Smith, R.J.G., Dupe, R.J., English, P.D., Green, J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 290: 505 (1981).

    Article  PubMed  CAS  Google Scholar 

  5. Smith, R.A.G., Dupe, R.J., English, P.D., Green, J. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis. Thromb. Haemost. 47: 269 (1982).

    PubMed  CAS  Google Scholar 

  6. Dupe, R.J., Englil, P.D., Smith, R.A.G., Green, J. Acyl-enzymes as thrombolytic agents in dog models of venous thrombosis and pulmonary embolism. Thromb. Haemost. 51: 248 (1984).

    PubMed  CAS  Google Scholar 

  7. Matsuo, O., Collen, D, Verstraete, M. On the fibrinolytic and thrombolytic properties of active-site p-anisoylated streptokinase plasminogen complex (BRL 26921). Thromb. Res. 24: 347 (1981).

    Article  PubMed  CAS  Google Scholar 

  8. Walker, I.D., Davidson, J.D., Rae, A.P., et. al Acylated streptokinase-plasminogen complex in patients with acute myocardial infarction. Thromb. Haemost. 51: 204 (1984).

    PubMed  CAS  Google Scholar 

  9. Marder, V.J., Rothbard, R.L., Fitzpatrick, P.G., et. al. Dose response study of intravenous acylated streptokinase: plasmin complex (BRL 26921) in coronary artery thrombosis. Circ. (Suppl.) 70: II–29 (1984)

    Google Scholar 

  10. van Rey, F.J., Bonnier, H.J., Michels, H.R., et. al. Efficacy and safety of BRL 26921, a new fibrinolytic agent for intravenous administration in acute myocardial infarction. Circ. (Suppl.) 70: II–330 (1984).

    Google Scholar 

  11. Been, M., de Bono, D.P., Hillis W.S., Hornung, R. Coronary thrombo- lysis with intravenous BRL 26921, an acylated plasminogen streptokinase complex. Circ. (Suppl.) 70: II–330 (1984).

    Google Scholar 

  12. Lammle, B., Noll, G., Tran, T.H., et. al. In vitro effects of the acylated streptokinase plasminogen activator complex BRL 33575 incubated with normal human plasma. Thromb. Haemost. 51:403 (1984).

    PubMed  CAS  Google Scholar 

  13. Husain, S.S., Gurewich, V., Lipinski, B. Purification and partial characterization of a single-chain high molecular weight form of urokinase from human urine. Arch. Biochem. Biophys. 220: 31 (1983).

    Article  PubMed  CAS  Google Scholar 

  14. Gurewich, V., Pannell, R., Louie, S., et. al. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (Pro-urokinase). J. Clin. Invest. 73: 1731 (1984).

    Article  PubMed  CAS  Google Scholar 

  15. Collen, D., Stassen, J.M., Blaber, M, et. al. Biological and thrombolytic properties of proenzyme and active forms of human urokinase-III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb. Haemost. 52: 27 (1984).

    PubMed  CAS  Google Scholar 

  16. Rijken, D.C., Wijngaards, G., Zoal-De Jong, M., Welberger, J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochem. Biophys. Acta. 580: 140 (1979).

    PubMed  CAS  Google Scholar 

  17. Rijken, D.C., Collen, D. Purification and characterisation of the plasminogen activator secreted by human melanoma cells in culture. J. Biol. Chem. 256: 7035 (1981).

    PubMed  CAS  Google Scholar 

  18. Rijken, D.C., Hoylaerts, M., Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J. Biol. Chem. 257: 2920 (1982).

    PubMed  CAS  Google Scholar 

  19. Collen, D., Stassen, J.M., Marafino, B., et. al. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. J. Pharm. Exp. Ther. 231: 146 (1984).

    CAS  Google Scholar 

  20. Hoylaerts, M., Rijken, D.C., Lijnen, H.R., Collen, D. Kinetics of the activation of plasminogen by human tissue plasminogen activator J. Biol. Chem. 257: 2912 (1982).

    PubMed  CAS  Google Scholar 

  21. Sobel, B.E., Gross, R.W., Robison, A.K. Thrombolysis, clot selectivity and kinetics. Circ. 70: 160 (1984).

    Article  CAS  Google Scholar 

  22. Fedullo, P.D., Konopkâ, R.G., Hartman, M.T., Moser, K.M. Thrombolysis with recombinant human tissue type plasminogen activator in a canine model of venous thrombosis. Circ. (Suppl.) 70: II–366 (1984).

    Google Scholar 

  23. Van de Werf, F., Bergman, S.E., Fox, K.A.A., et. al. Coronary thrombolysis with intravenously administered human tissue type plasminogen activator produced by recombinant DNA technology. Circ. 69: 605 (1984).

    Article  Google Scholar 

  24. Gold, A.K., Fallon, J.T. Yasuda, T., et. al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circ. 70: 700 (1984).

    Article  CAS  Google Scholar 

  25. Flameng, W., Van de Werf, F., Van Haecke, J., et. al. Coronary thrombolysis in baboons after intravenous administration of recombinant tissue-type plasminogen activator. J. Clin. Invest. 75: 84 (1985).

    Article  PubMed  CAS  Google Scholar 

  26. Tiefenbrunn, A.J., Robison, A.K., Kurnik P.B., et. al. Clinical pharmacology in patients with evolving myocardial infarction of tissue-type plasminogen activator produced by recombinant DNA technology. Circ. 71: 110 (1985).

    Article  CAS  Google Scholar 

  27. Grossband, E., Gold, H.K., Tiefenbrunn, A.J., et. al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circ. (Suppl.) 70: II–27 (1984).

    Google Scholar 

  28. Collen, D., Topol, E.J., Tiefenbrunn, A.J., et. al Coronary thrombolysis with recombinant human tissue-type plasminogen activator: A prospective randomized placebo controlled trial. Circ. 70: 1012 (1984).

    Article  CAS  Google Scholar 

  29. Williams, D.O., For the TIMI Investigators Intravenous recombinant tissue-type plasminogen activator in acute myocardial infarction: A report from the NHLBI thrombolysis in myocardial infarction trial. J. Am. Coll. Card. 5: 495 (1985).

    Article  Google Scholar 

  30. The TIMI Study Group The thrombolysis in myocardial infarction trial: Phase I findings. New Engl. J. Med. 312: 932 (1985).

    Google Scholar 

  31. Verstraete, M., Bory, M., Collen, D.C., et. Al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet 1: 842 (1985).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genentech, Inc., South San Francisco, Cal, 94080, USA

    E. Grossbard (Associate Director of Clinical Research)

Authors
  1. E. Grossbard
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Duke University Medical Center, Durham, North Carolina, USA

    Robert M. Califf  & Galen S. Wagner  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Martinus Nijhoff Publishing, Boston

About this chapter

Cite this chapter

Grossbard, E. (1985). Novel Thrombolytic Drugs. In: Califf, R.M., Wagner, G.S. (eds) Acute Coronary Care 1986. Acute Coronary Care Updates, vol 1. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2633-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-2633-5_5

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-9645-4

  • Online ISBN: 978-1-4613-2633-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation